Market access in the US
Patient access to treatments is becoming more complex in the US. The biggest challenge is the vast number of “unknowns” as payers continue to shave budgets and pricing and prescription drug programs are overhauled.
The resources on this page show some of the ways in which manufacturers are navigating the best route to optimal reimbursement and market access for their products.
____
Recommendations for developing a robust ICER strategy
This paper explains why engagement in the ICER value assessment process is beneficial for manufacturers seeking to address cost-effectiveness concerns. It also offers recommendations for developing a robust ICER strategy.
The project work was awesome and your team have been fantastic from start to finish – responsive and prompt to take action. I will choose PRMA Consulting again.
Associate Director Global Market Access and Pricing, top-5 pharmaceutical company
A job well done! Many thanks for turning this project around so quickly to meet our needs for the product launch. We couldn’t have done it without your support.
Market Access Manager, top-5 pharmaceutical company
What an amazing job. Your expertise, responsiveness, and ‘one team’ collaboration surpassed our expectations. We made the right choice to partner with you.
Head of Payer Value Strategy, leading pharmaceutical company
I have recommended PRMA Consulting to my colleagues in the US and Europe. Your knowledge of local markets is outstanding and the quality of the deliverable was exceptional.
Director, HTA and Value Frameworks, leading pharmaceutical company
Thank you for the very thorough, high quality, and tremendously useful piece of work you have completed. This is what I call ‘value for money’.
Global Reimbursement Director, top-20 pharmaceutical company
You have a vision; we are the consulting partner that will get you there.
We would be delighted to have a confidential conversation about your market access needs.
